Publications by the researcher in collaboration with Jesús Egido de los Ríos (16)

2014

  1. Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice

    Journal of Cellular and Molecular Medicine, Vol. 18, Núm. 4, pp. 721-734

2013

  1. Proteomic analysis of intraluminal thrombus highlights complement activation in human abdominal aortic aneurysms

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, Núm. 8, pp. 2013-2020

  2. Unraveling biomarkers of abdominal aortic aneurisms by iTRAQ analysis of depleted plasma

    Methods in Molecular Biology, Vol. 1000, pp. 157-166

2012

  1. Metabolomic study of plasma of patients with abdominal aortic aneurysm

    Analytical and Bioanalytical Chemistry, Vol. 403, Núm. 6, pp. 1651-1660

  2. Plasma profiling by a protein array approach identifies IGFBP-1 as a novel biomarker of abdominal aortic aneurysm

    Atherosclerosis, Vol. 221, Núm. 2, pp. 544-550

2011

  1. Animal models of cardiovascular diseases

    Journal of Biomedicine and Biotechnology, Vol. 2011

2009

  1. Leukotriene B4 enhances the activity of nuclear factor-κB pathway through BLT1 and BLT2 receptors in atherosclerosis

    Cardiovascular Research, Vol. 81, Núm. 1, pp. 216-225

2008

  1. Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome††Conflicts of interest: Drs. Egido and Tuñón have participated on advisory boards and have been invited speakers for Pfizer.

    American Journal of Cardiology, Vol. 102, Núm. 1, pp. 12-18

2007

  1. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis

    Journal of Pharmacology and Experimental Therapeutics, Vol. 320, Núm. 1, pp. 108-116

2006

  1. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization

    Journal of Cardiovascular Pharmacology, Vol. 47, Núm. 1, pp. 60-69

  2. El tratamiento con dosis altas de atorvastatina disminuye la inflamación en la aterosclerosis carotídea humana

    Clínica e investigación en arteriosclerosis, Vol. 18, Núm. 1, pp. 18-23

  3. Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB

    Atherosclerosis, Vol. 187, Núm. 1, pp. 139-149

2005

  1. HMG-CoA reductase inhibitors reduce IκB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells

    Journal of Cardiovascular Pharmacology, Vol. 45, Núm. 5, pp. 468-475

  2. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month

    Stroke, Vol. 36, Núm. 8, pp. 1796-1800

2004

  1. NF-κB Activation and Fas Ligand Overexpression in Blood and Plaques of Patients with Carotid Atherosclerosis: Potential Implication in Plaque Instability

    Stroke, Vol. 35, Núm. 2, pp. 458-463

2002

  1. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells

    Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58